



Press Release | Lyon, France, December 19<sup>th</sup> 2018

**SEQENS. A new name for a global leader in pharmaceutical synthesis and specialty ingredients.**

Novacap and all its activities unify their names into a new one and become SEQENS.

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering unrivalled market responsiveness and tailor-made solutions to our customers.

SEQENS operates 24 manufacturing plants and 3 R&D centers in Europe, North America and Asia with 3,200 employees. More than 300 scientists, engineers and experts develop tailor-made solutions for our customers and ensure that products are successfully transferred into production.

**SEQENS. Taking science to next level**

SEQENS refers naturally to our core synthesis activities, mixed with that sequencing idea in which we arrange molecules, competencies and technologies to take science to the next level.

In the pharmaceutical industry, SEQENS supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products.

SEQENS also develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.

**SEQENS. The Continuum of Progress**

“As SEQENS, we intend to stand as a strong, global and integrated player in pharmaceutical synthesis and specialty ingredients. Our mission is to bring R&D and industrial performance to our clients’ projects. From now on, we want to better leverage on our strong expertise to develop and produce highly complex molecules with unique skills and the largest continuum of technologies available on the market.

I am proud of what we have achieved so far, on behalf of SEQENS’ 3,200 scientists, engineers, and experts working across a range of fields such as QHSE, industrial methods and processes, quality, sales and marketing, finance, innovation, legal and more,” says Pierre Luzeau, SEQENS CEO.

## **About SEQENS**

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients.

With 24 manufacturing sites and 3 R&D centers in Europe, North America and Asia, SEQENS develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.

Driven by a culture of excellence and a strong entrepreneurial spirit, SEQENS' 3,200 employees are committed to providing its customers with the highest level of service and product quality while acting ethically in the frame of its Corporate Social Responsibility program.

More information on [www.seqens.com](http://www.seqens.com)

Contact Seqens: [press@seqens.com](mailto:press@seqens.com)

## **About Novacap**

The Novacap Group subsidiaries – Novacarb, Novacyl, Novapex, Novacid, Novabay, Uetikon, H2B, ID Bio, PCAS, Chemoxy and PCI Synthesis – boast leading positions in a variety of markets, including cosmetics and fragrances, food and feed, home care, environment or electronics.

The legal entities of Novacarb, Novacyl, Novapex, Novacid, Novabay, Uetikon, H2B, ID Bio, PCAS, Chemoxy and PCI Synthesis will remain in place.

More information on [www.novacap.eu](http://www.novacap.eu)